About Gad A. Getz, PhD

Professor of Pathology, Harvard Medical School
Director of Bioinformatics, Mass General Cancer Center and Department of Pathology
Director of Cancer Bioinformatics, Broad Institute of Harvard and MIT
Paul Zamecnik, MD Endowed Chair in Oncology Basic Research, Mass General Cancer Center

Contact email: ggetz1@mgh.harvard.edu


Inaugural Krantz Awards Recipient

2023 Spark Award: Developing deep learning molecular language model for cancer drug discovery
Gad A. Getz, PhD

Learn more about the Krantz Awards


The Getz laboratory is focused on cancer genome analysis, which includes two major steps: (i) Characterization – cataloging of all genomic events and the mechanisms that created them during the clonal evolution of cancer (starting from normal cells and progressing to premalignancy, primary cancer, and emergence of resistance), comparing events at the DNA, RNA, and protein levels between one or more tumor and normal samples from an individual patient; and (ii) Interpretation – analysis of the characterization data across a cohort of patients with the aim of identifying the alterations in genes and pathways that drive cancer progression, drive resistance, or increase its risk as well as identifying molecular subtypes of the disease, their markers, and relationship to clinical variables. Recently, the Getz lab is also studying the tumor and its immune microenvironment using both bulk and single-cell RNA-sequencing (RNA-seq) data. In addition to developing tools for high throughput analysis of cancer data and experimentally testing the findings, the Getz lab develops computer platforms that enable largescale analytics and visualization.

Read more about the Getz Lab from the Krantz Family Center for Cancer Research Annual Report and the Pathology Basic Science Research Brochure.

Selected Publications

Bibliography of Gad Getz via PubMed

Leshchiner I, Mroz EA, Cha J, Rosebrock D, Spiro O, Bonilla-Velez J, Faquin WC, Lefranc-Torres A, Lin DT, Michaud WA, Getz G, Rocco JW. Inferring early genetic progression in cancers with unobtainable premalignant disease. Nat Cancer. 2023 Apr;4(4):550-563.

Knisbacher BA, Lin Z, Hahn CK, Nadeu F, Duran-Ferrer M, Stevenson KE, Tausch E, Delgado J, Barbera-Mourelle A, Taylor-Weiner A, Bousquets-Muñoz P, Diaz-Navarro A, Dunford A, Anand S, Kretzmer H, Gutierrez-Abril J, López-Tamargo S, Fernandes SM, Sun C, Sivina M, Rassenti LZ, Schneider C, Li S, Parida L, Meissner A, Aguet F, Burger JA, Wiestner A, Kipps TJ, Brown JR, Hallek M, Stewart C, Neuberg DS, Martín-Subero JI, Puente XS, Stilgenbauer S, Wu CJ, Campo E, Getz G. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. 2022 Nov;54(11):1664-1674.

Boiarsky R, Haradhvala NJ, Alberge JB, Sklavenitis-Pistofidis R, Mouhieddine TH, Zavidij O, Shih MC, Firer D, Miller M, El-Khoury H, Anand SK, Aguet F, Sontag D, Ghobrial IM, Getz G. Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. Nat Commun. 2022 Nov 17;13(1):7040.